Cargando…
Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
PURPOSE: To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. METHOD...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087571/ https://www.ncbi.nlm.nih.gov/pubmed/30151278 http://dx.doi.org/10.1155/2018/5612342 |
_version_ | 1783346700596805632 |
---|---|
author | Giancipoli, Ermete Pinna, Antonio Boscia, Francesco Zasa, Gianluigi Sotgiu, Giovanni Dore, Simone D'Amico Ricci, Giuseppe |
author_facet | Giancipoli, Ermete Pinna, Antonio Boscia, Francesco Zasa, Gianluigi Sotgiu, Giovanni Dore, Simone D'Amico Ricci, Giuseppe |
author_sort | Giancipoli, Ermete |
collection | PubMed |
description | PURPOSE: To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. METHODS: In this randomized, controlled pilot study, 16 eyes of 15 patients, unresponsive to anti-VEGF therapy, were enrolled and randomly assigned to two groups: DXI + anti-VEGF (treatment group: 11 eyes) and monthly anti-VEGF alone (control group: 5 eyes). Patients were treated at baseline and followed for 6 months. Best corrected visual acuity (BCVA), optical coherence tomography (OCT) parameters, and fluorescein angiography (FA) were evaluated. RESULTS: Eight eyes (72.7%) in the treatment group and 2 eyes in the control group (40%) showed complete retinal fluid resorption (p=0.049). BCVA showed no significant change from baseline in both the treatment group and the control group (p=0.40 and p=0.29, respectively). Both median central foveal thickness (CFT) and median macular volume showed a greater reduction from baseline in the treatment group. CONCLUSION: In patients showing an incomplete response to anti-VEGF therapy, DXI combined with intravitreal anti-VEGF seems to improve retinal fluid resorption without functional advantage. This trial is registered with ACTRN12618001102268. |
format | Online Article Text |
id | pubmed-6087571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-60875712018-08-27 Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study Giancipoli, Ermete Pinna, Antonio Boscia, Francesco Zasa, Gianluigi Sotgiu, Giovanni Dore, Simone D'Amico Ricci, Giuseppe J Ophthalmol Clinical Study PURPOSE: To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. METHODS: In this randomized, controlled pilot study, 16 eyes of 15 patients, unresponsive to anti-VEGF therapy, were enrolled and randomly assigned to two groups: DXI + anti-VEGF (treatment group: 11 eyes) and monthly anti-VEGF alone (control group: 5 eyes). Patients were treated at baseline and followed for 6 months. Best corrected visual acuity (BCVA), optical coherence tomography (OCT) parameters, and fluorescein angiography (FA) were evaluated. RESULTS: Eight eyes (72.7%) in the treatment group and 2 eyes in the control group (40%) showed complete retinal fluid resorption (p=0.049). BCVA showed no significant change from baseline in both the treatment group and the control group (p=0.40 and p=0.29, respectively). Both median central foveal thickness (CFT) and median macular volume showed a greater reduction from baseline in the treatment group. CONCLUSION: In patients showing an incomplete response to anti-VEGF therapy, DXI combined with intravitreal anti-VEGF seems to improve retinal fluid resorption without functional advantage. This trial is registered with ACTRN12618001102268. Hindawi 2018-07-29 /pmc/articles/PMC6087571/ /pubmed/30151278 http://dx.doi.org/10.1155/2018/5612342 Text en Copyright © 2018 Ermete Giancipoli et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Giancipoli, Ermete Pinna, Antonio Boscia, Francesco Zasa, Gianluigi Sotgiu, Giovanni Dore, Simone D'Amico Ricci, Giuseppe Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
title | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
title_full | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
title_fullStr | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
title_full_unstemmed | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
title_short | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
title_sort | intravitreal dexamethasone in patients with wet age-related macular degeneration resistant to anti-vegf: a prospective pilot study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087571/ https://www.ncbi.nlm.nih.gov/pubmed/30151278 http://dx.doi.org/10.1155/2018/5612342 |
work_keys_str_mv | AT giancipoliermete intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT pinnaantonio intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT bosciafrancesco intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT zasagianluigi intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT sotgiugiovanni intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT doresimone intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT damicoriccigiuseppe intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy |